HIF-2 complex dissociation, target inhibition, and acquired resistance with PT2385, a first-in-class HIF-2 inhibitor, in patients with clear cell renal cell carcinoma

Kevin D. Courtney, Yuanqing Ma, Alberto Diaz de Leon, Alana Christie, Zhiqun Xie, Layton Woolford, Nirmish Singla, Allison Joyce, Haley Hill, Ananth J. Madhuranthakam, Qing Yuan, Yin Xi, Yue Zhang, Jenny Chang, Oluwatomilade Fatunde, Yull Arriaga, Arthur E. Frankel, Sanjeeva Kalva, Song Zhang, Tiffani McKenzieOscar Reig Torras, Robert A. Figlin, Brian I. Rini, Renee M. McKay, Payal Kapur, Tao Wang, Ivan Pedrosa, James Brugarolas

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'HIF-2 complex dissociation, target inhibition, and acquired resistance with PT2385, a first-in-class HIF-2 inhibitor, in patients with clear cell renal cell carcinoma'. Together they form a unique fingerprint.

Medicine & Life Sciences